Abstract
Background: In 2017, the hepatitis C treatment regimens sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) and glecaprevir/pibrentasvir (G/P) received ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
